Antibody therapy in renal cell carcinoma.

World J Urol · 2008 · PMC2295251 · PMID 18239922

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendP = 0.0670so close (0.05 < p ≤ 0.1)

Additionally, the combination treatment showed a trend toward improved overall survival ( P = 0.0670), which leads to the conclusion that the combination of Bevacizumab with IFN-α2a is superior to either of the single treatment regimens in mRCC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.